ConductScience.org, home

Disease · MONDO_0005114

pneumococcal infection

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. pneumococcal infection. Diseases, record MONDO_0005114. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005114

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
pneumococcal infection
Open Targets
Open Targets ID
MONDO_0005114
Open Targets
Other names
INFECT PNEUMOCOCCAL, INFECT STREP PNEUMONIAE, Infection, Pneumococcal, Infection, Streptococcus pneumoniae, Infections, Pneumococcal, Infections, Streptococcus pneumoniae, PNEUMOCOCCAL INFECT, Pneumococcal Infections, Pneumococcal infection, NOS, Pneumococcal infectious disease (disorder), Pneumococcal infectious disease, NOS, STREP PNEUMONIAE INFECT, Streptococcus pneumoniae Infection, Streptococcus pneumoniae Infections, Streptococcus pneumoniae caused disease or disorder, Streptococcus pneumoniae disease or disorder, Streptococcus pneumoniae infectious disease, pneumococcal infectious disease, pneumoniae Infection, Streptococcus, pneumoniae Infections, Streptococcus
Open Targets
MeSH
D011008
MeSH
Highest stage of its drugs
Approval, for 1 of its 5 drugs, from FDA
Open Targets

Drugs5

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197CHEMBL6068493Vaccine componentApprovalFDA861Drugs and targets
KP-1461CHEMBL4297297Small moleculePhase 2TTD100Drugs and targets
AMOXICILLINCHEMBL1082Small moleculeUnknownClinicalTrials.gov111Drugs and targets
INFLUENZA A VIRUS, SPLIT VIRIONCHEMBL6068363Vaccine componentUnknownClinicalTrials.gov110Drugs and targets
INFLUENZA VIRUS VACCINECHEMBL2109042Vaccine componentUnknownClinicalTrials.gov110Drugs and targets

Targets0

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

None in this release.

Trials2

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 6 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT01509105Prevenar13 Post Market Surveillance6492017-02-13HealthySTREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197Its record names the diseaseClinicalTrials.gov
NCT05361499A Controlled Human Pneumococcal Infection Model (PIM) StudyNot applicable20Streptococcus Pneumoniae InfectionAMOXICILLINIts record names the diseaseClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005114

GET https://conductscience.org/api/diseases/v1/MONDO_0005114/drugs